AR009013A1 - Aplicacion de la hcg (gonadotrofinacorionica humana), subunidades beta, fragmentos activos y derivados de los mismos como inhibidores de las matricesde metaloproteinas y composiciones farmaceuticas que incluyen dichos inhibidores - Google Patents

Aplicacion de la hcg (gonadotrofinacorionica humana), subunidades beta, fragmentos activos y derivados de los mismos como inhibidores de las matricesde metaloproteinas y composiciones farmaceuticas que incluyen dichos inhibidores

Info

Publication number
AR009013A1
AR009013A1 ARP970103577A ARP970103577A AR009013A1 AR 009013 A1 AR009013 A1 AR 009013A1 AR P970103577 A ARP970103577 A AR P970103577A AR P970103577 A ARP970103577 A AR P970103577A AR 009013 A1 AR009013 A1 AR 009013A1
Authority
AR
Argentina
Prior art keywords
inhibitors
hcg
pharmaceutical compositions
application
active fragments
Prior art date
Application number
ARP970103577A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR009013A1 publication Critical patent/AR009013A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se trata de la aplicacion de la gonadotrofina corionica humana (HCG), los fragmentos y derivados activos de la misma, o nucleo beta de HCG en lapreparacion de un medicamento para la profilaxis y/o el tratamiento de patologías querequieren de la inhibicion de la actividad enzimática de lamatriz metaloproteasa (MMP). También se proponen composiciones farmacéuticas formuladas con dichas inhibiciones.
ARP970103577A 1996-08-07 1997-08-06 Aplicacion de la hcg (gonadotrofinacorionica humana), subunidades beta, fragmentos activos y derivados de los mismos como inhibidores de las matricesde metaloproteinas y composiciones farmaceuticas que incluyen dichos inhibidores AR009013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96RM000566A IT1284876B1 (it) 1996-08-07 1996-08-07 Hcg come inibitore della collagenasi

Publications (1)

Publication Number Publication Date
AR009013A1 true AR009013A1 (es) 2000-03-08

Family

ID=11404385

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970103577A AR009013A1 (es) 1996-08-07 1997-08-06 Aplicacion de la hcg (gonadotrofinacorionica humana), subunidades beta, fragmentos activos y derivados de los mismos como inhibidores de las matricesde metaloproteinas y composiciones farmaceuticas que incluyen dichos inhibidores

Country Status (14)

Country Link
US (1) US6444639B2 (es)
EP (1) EP0920330B1 (es)
JP (1) JP3996952B2 (es)
AR (1) AR009013A1 (es)
AT (1) ATE228372T1 (es)
AU (1) AU732972B2 (es)
CA (1) CA2262582C (es)
DE (1) DE69717463T2 (es)
DK (1) DK0920330T3 (es)
ES (1) ES2183205T3 (es)
IL (1) IL128399A (es)
IT (1) IT1284876B1 (es)
PT (1) PT920330E (es)
WO (1) WO1998005353A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2005077404A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
CA2582567A1 (en) 2004-10-07 2006-04-13 Stem Cell Therapeutics Corp. Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
AU2007229301B2 (en) 2006-03-17 2013-08-01 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
CA2954893A1 (en) * 2014-07-15 2016-01-21 Zietchick Research Institute, Llc Method for preventing or treating ocular disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1250075B (it) 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5677275A (en) * 1994-08-05 1997-10-14 The United States Of America As Represented By The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
WO1997014428A1 (en) 1995-10-16 1997-04-24 Applied Research Systems Use of human chorionic gonadotropin in the treatment of kaposi's sarcoma
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin

Also Published As

Publication number Publication date
DK0920330T3 (da) 2002-12-30
CA2262582C (en) 2009-02-24
ATE228372T1 (de) 2002-12-15
IL128399A0 (en) 2000-01-31
ITRM960566A0 (es) 1996-08-07
EP0920330A1 (en) 1999-06-09
ITRM960566A1 (it) 1998-02-07
IT1284876B1 (it) 1998-05-22
DE69717463D1 (de) 2003-01-09
PT920330E (pt) 2003-02-28
US20010006940A1 (en) 2001-07-05
JP2000516582A (ja) 2000-12-12
IL128399A (en) 2006-10-05
AU3771197A (en) 1998-02-25
ES2183205T3 (es) 2003-03-16
EP0920330B1 (en) 2002-11-27
WO1998005353A1 (en) 1998-02-12
JP3996952B2 (ja) 2007-10-24
US6444639B2 (en) 2002-09-03
AU732972B2 (en) 2001-05-03
DE69717463T2 (de) 2003-07-10
CA2262582A1 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
AR023129A1 (es) Composiciones para mejorar la fertilidad
AR005650A1 (es) Metodo para inhibir el fotoenvejecimiento de la piel humana no danada por la radiacion uvb mediante inhibidores de la sintesis y/o actividad de mmp y lautilizacion de dichos inhibidores en la preparacion de medicamentos para prevenir dicho envejecimiento.
PT98710A (pt) Processo de preparacao de compostos de indolilo substituidos e de composicoes farmaceuticas que os contem
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
BR9811099A (pt) Inibidores de urocinase
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BR0116402A (pt) Derivados de tetrahidropiridina, sua preparação e sua utilização como inibidores de proliferação celular
ES2145913T3 (es) Inhibidores de metaloproteasas.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
BR0010568A (pt) Composição farmacêutica, tecido estromal tri-dimensional, substância alimentìcia, suplemento nutricional, métodos para fabricar uma composição farmacêutica, para uma melhorada cicatrização de feridas ou queimaduras, para fabricar uma composição cosmética, para a correção de um defeito cosmético, para inibir ou reverter os efeitos deletérios para células em uma pessoa, para estimular o crescimento de cabelo, e para isolar colágeno
UY27370A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células y métodos para su utilización
ES2143132T3 (es) Monohidratos de derivado de acido aminobenceno-sulfonico y su metodo de preparacion.
BR0008491A (pt) Inibidores de metaloprotease de ácido hidrox mico de sulfona aromática
AR024138A1 (es) Inhibidores de la proliferacion celular
MX9306220A (es) Ptp 1d: una proteina tirosina fosfatasa novedosa.
ES2110414T3 (es) Derivados de sacarina utiles como inhibidores de enzimas proteoliticas y su preparacion.
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
AR026197A1 (es) Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
AR009013A1 (es) Aplicacion de la hcg (gonadotrofinacorionica humana), subunidades beta, fragmentos activos y derivados de los mismos como inhibidores de las matricesde metaloproteinas y composiciones farmaceuticas que incluyen dichos inhibidores
ATE221780T1 (de) Fenbendazolformulierungen
AR000357A1 (es) Utilización de un antagonista de sustancia p para la preparación de una composición farmacéutica de aplicación topica para tratar las manchas rojas cutaneas de origen neurogeno y especialmente la rosacea y el eritema pudico

Legal Events

Date Code Title Description
FC Refusal